Current Report Filing (8-k)
December 12 2017 - 9:10AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 12, 2017
ADURO BIOTECH, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-37345
|
|
94-3348934
|
(State or Other Jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of Incorporation)
|
|
File Number)
|
|
Identification No.)
|
740 Heinz Avenue
Berkeley, California 94710
(Address of Principal Executive Offices) (Zip Code)
Registrants telephone number, including area code:
(510) 848-4400
Check the appropriate box below if the
Form 8-K
filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to
Rule 14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to
Rule 14d-2(b) under
the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to
Rule 13e-4(c) under
the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§ 240.12b-2
of
this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
On December 12, 2017, Aduro Biotech, Inc. issued a press release
titled Aduro Biotech Provides Update on
CRS-207
Programs, which is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01
|
Financial Statements and Exhibits
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
A
DURO
B
IOTECH
, I
NC
.
|
|
|
|
|
Dated: December 12, 2017
|
|
|
|
By:
|
|
/s/ Jennifer Lew
|
|
|
|
|
|
|
Jennifer Lew
|
|
|
|
|
|
|
Senior Vice President of Finance
|
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Apr 2024 to May 2024
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Aduro Biotech Inc (NASDAQ): 0 recent articles
More Aduro Biotech, Inc. News Articles